2015
DOI: 10.1089/scd.2015.0074
|View full text |Cite
|
Sign up to set email alerts
|

Involvement of Immune Responses in the Efficacy of Cord Blood Cell Therapy for Cerebral Palsy

Abstract: This study evaluated the efficacy of umbilical cord blood (UCB) cell for patients with cerebral palsy (CP) in a randomized, placebo-controlled, double-blind trial and also assessed factors and mechanisms related to the efficacy. Thirty-six children (ages 6 months to 20 years old) with CP were enrolled and treated with UCB or a placebo. Muscle strength and gross motor function were evaluated at baseline and 1, 3, and 6 months after treatment. Along with function measurements, each subject underwent (18)F-fluoro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

9
98
3
2

Year Published

2017
2017
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 80 publications
(112 citation statements)
references
References 42 publications
9
98
3
2
Order By: Relevance
“…Failure or poor results following attempts of MSC-based therapy observed in a significant number of patients raised at least three concerns. First is their overall viability following infusion via the route used (local versus systemic 43 ); moreover, despite clinical evidence and reports from experimental models supporting the assumption that MSC homing may be governed by damaged tissues, MSCs can still be found in unwanted sites, thereby raising safety concerns for the long-term effects of MSC-based therapy 59,60 , particularly in pediatric patients 61-63 . Second is the engraftment degree of MSCs in targeted tissues, and the third, as a consequence, is the fate of these cells if improperly engrafted.…”
Section: Mscs Regenerative Medicine and Cell Therapymentioning
confidence: 99%
“…Failure or poor results following attempts of MSC-based therapy observed in a significant number of patients raised at least three concerns. First is their overall viability following infusion via the route used (local versus systemic 43 ); moreover, despite clinical evidence and reports from experimental models supporting the assumption that MSC homing may be governed by damaged tissues, MSCs can still be found in unwanted sites, thereby raising safety concerns for the long-term effects of MSC-based therapy 59,60 , particularly in pediatric patients 61-63 . Second is the engraftment degree of MSCs in targeted tissues, and the third, as a consequence, is the fate of these cells if improperly engrafted.…”
Section: Mscs Regenerative Medicine and Cell Therapymentioning
confidence: 99%
“…By comparison, in South Korea all advanced cell therapy for cerebral palsy has always been with allogeneic cord blood since the first registered trial in 2010 (NCT01193660). The ability to use allogeneic cells has enabled trials in South Korea to accrue patients much faster than the autologous trials in the USA, and the first publications that demonstrate the efficacy of perinatal cell therapy for cerebral palsy against control groups are from the South-Korea research pipeline [51][52][53]. This history illustrates that even the most thorough compilation of registered trials will still miss important emerging research that has not been registered, either because the trial is Phase I, or the host country does not require international trial registration, or the patients are treated under a compassionate exemption.…”
Section: Resultsmentioning
confidence: 99%
“…There is currently no specific treatment for CP except for rehabilitation training in the clinic (Maclennan et al, ). Since the first transplantation of UCBCs was performed in 1988 (Mreboredo, Diaz, Castro, & Villaescusa, ), UCB‐SC therapy has been widely studied in children with CP, and improved brain cognition and gross motor function have been shown with no serious side effects indicating that the therapy is neuroprotective and safe (Feng et al, ; Huang et al, ; Kang et al, ; Lee et al, ; Min et al, ; Romanov et al, ; Sun et al, ) (Table ). However, current clinical trials focused on UCB‐SC therapy in children with CP have not considered the gestational age partition of the patients, and thus further research is needed regarding children with CP who were born prematurely.…”
Section: Ucb‐sc Therapy In Preterm Brain Injuries and Neurological Sementioning
confidence: 99%